News & Media

Oct 30 – Curetis To Attend Key Conferences in the Fourth Quarter of 2019

Oct 28 – Curetis Group Company Ares Genetics launches AI-Powered Molecular Antibiotic Susceptibility Test

Sep 18 – Curetis Reports Financial Results for the First Six Months of 2019

Sep 16 – Curetis Group Subsidiary Ares Genetics Signs R&D and Option Agreement with leading Global IVD Corporation

Sep 04 – Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

Aug 12 – Curetis Retains H.C. Wainwright & Co. as Strategic Advisor

Aug 08 – Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing

Aug 01 – Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes

Jul 30 – Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region

Jul 25 – Curetis To Present at Solebury Trout European Biotech Investor Day in NYC

Jul 23 – Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

Jul 04 – Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Jul 02 – Curetis To Attend Key Conferences in the Third Quarter of 2019

Jun 28 – Curetis Reports Results of the Annual General Meeting Held on June 27, 2019

Jun 04 – New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

May 23 – Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

May 21 – Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

May 17 – Curetis Announces Financial Results for the first Three Months of 2019

May 15 – Curetis to Hold Annual General Shareholders’ Meeting on June 27,2019

Apr 12 – Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019

Apr 11 – Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019

Apr 05 – Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019

Apr 04 – Curetis: Study Data Presented at ECCMID 2019 Confirm Clinical Beneftis of Unyvero Platform

Apr 02 – Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNA Testing for Antibiotic Resistance

Apr 01 – Curetis To Attend Key Conferences in the Second Quarter of 2019

Mar 26 – Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero

Feb 18 – Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance

Feb 04 – Curetis’ Partner Beijing Clear Biotech Submits Filing for Unyvero Approval in China

Jan 30 – Curetis’ Unyvero Application Cartridges Receive Regulatory Approvals in Malaysia and Thailand

Jan 08 – Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Dec 18 – Curetis’ Subsidiary Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance

Dec 13 – Curetis Sharpens Focus on Near-Term Strategic Value Drivers

Nov 23 – Curetis Announces Financial Results for the First Nine Months of 2018

Nov 23 – Curetis Accelerates 510(k) Submission Preparation for Unyvero

Oct 11 – Curetis, Beijing Clear Biotech Expand Strategic Collaboration for Unyvero in Greater China

Oct 02 – Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes

Sep 28 – Curetis Publishes Interim Report for the First Half-Year 2018

Sep 17 – Curetis To Attend Key Investor and Scientific Conferences In The Fourth Quarter 2018

Sep 04 – Curetis’ Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test

Aug 14 – Curetis Announces Change in Curetis USA Inc. Management

Aug 14 – Curetis Announces Financial Results for the First Six Months of 2018

Aug 07 – Curetis to Report its Half-Year Results 2018 on August 14, 2018

Aug 07 – Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets

Jul 31 – Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program

Jun 21 – Curetis Reports Results of the Annual General Meeting Held on June 21, 2018

Jun 12 – Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2018

Jun 07 – Curetis Launches Unyvero System and LRT Cartridge for Lower Respiratory Tract Infections in the U.S.

May 18 – Curetis Publishes Business and Financial Update for the First Quarter 2018

May 09 – Curetis to Hold Annual General Shareholders’ Meeting on June 21, 2018

Apr 30 – Curetis Announces Change of the Composition of Its Supervisory Board

Apr 30 – Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance For 2018

Apr 27 – Curetis to Raise EUR 4.1 Million in Equity Offering with Access to Additional USD 10 million in Equity Over 36 Months

Apr 23 – Curetis to Publish its 2017 Annual Results on April 30, 2018

Apr 19 – Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018

Apr 18 – Curetis: Novel Products and Study Data to be Presented at ECCMID 2018

Apr 11 – Curetis Establishes U.S. Scientific Advisory Board

Apr 04 – Curetis to Hold Investor Conference Call with Webcast on U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge today

Apr 04 – Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority

Apr 03 – Curetis Receives U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge

Mar 26 – Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018

Mar 14 – Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology

Mar 06 – Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley

Feb 06 – Curetis Unyvero HPN Application Receives Singapore Health Sciences Authority Approval; Updates on Sepsis Host Response Test

Feb 05 – Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project; Curetis Announces Non-Audited Financial Results for 2017

Jan 10 – Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

Jan 08 – Curetis Expects Near-Term FDA Decision on De Novo Request

Dec 19 – Curetis To Attend Key Investor and Scientific Conferences In The First Quarter 2018

Nov 16 – Curetis Publishes Business and Financial Update for the First Nine Months of 2017

Oct 23 – Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge

Oct 06 – Curetis to Present at Key Investor and Scientific Conferences in the Fourth Quarter 2017

Sep 12 – MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics

Aug 16 – Curetis Announces Financial Results for the First Six Months of 2017

Aug 16 – Curetis Announces Management Board Changes

Aug 15 – Curetis Partners with Biotest to support academic PEPPER Pentaglobin® Peritonitis Trial with Unyvero IAI Application

Aug 04 – Curetis to Report its Half-Year Results 2017 on August 16, 2017

Jul 07 – Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017

Jun 26 – “GEAR – Predicting Antibiotic Resistances with Genetic Data” Succeeds in Competition “Landmarks in the Land of Ideas”

Jun 23 – Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017

May 24 – Curetis Provides Business and Financial Update for the First Quarter 2017

May 24 – Curetis Provides Update on Unyvero LRT FDA 510(k) Submission

May 08 – Curetis to Hold Annual General Shareholders’ Meeting on June 23, 2017

Apr 27 – Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits

Apr 20 – Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking

Apr 12 – Curetis Expands Supervisory and Medical Advisory Boards

Apr 12 – Curetis Reports Full-Year 2016 Financial Results and Updates 2017 Guidance

Apr 10 – Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe

Apr 06 – Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing

Apr 04 – Curetis to Publish its Annual Results 2016 on April 12, 2017

Mar 29 – Curetis Announces Participation in Major Investor and Scientific Conferences in the Second Quarter 2017

Mar 08 – Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech

Jan 31 – Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers

Jan 05 – Curetis Files for U.S. FDA Clearance for Unyvero Platform and LRT Application Cartridge

Jan 04 – Curetis to Present at Key Investor and Scientific Conferences in the First Quarter 2017

Jan 04 – Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections

Dec 13 – Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec

Dec 13 – Curetis to host Conference Call and Webcast on EIB Debt Financing Facility and Gyronimo Asset Acquisition

Dec 12 – #investEU – Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform

Nov 18 – Curetis Publishes Business and Financial Update for the First Nine Months 2016

Oct 25 – Curetis Announces Positive Top Line Data from U.S. FDA Trial

Oct 04 – Curetis to Present at Several Investor and Scientific Conferences in the Fourth Quarter 2016

Sep 07 – Curetis to host conference call and webcast on GEAR acquisition

Sep 07 – Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens

Sep 06 – Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge

Aug 19 – Curetis Reports Financial Results for the First Six Months of 2016

Aug 01 – Curetis to Report its Half-Year Results 2016 on August 19, 2016

Jul 05 – Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary

Jul 01 – Curetis Announces Participation in Clinical, Scientific and Investor Meetings in the Third Quarter 2016

Jun 28 – Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections

Jun 17 – Curetis Reports Results of the Annual Shareholder Meeting Held on June 16, 2016

Jun 15 – Curetis Announces Excellent Study Data and Multi-Region Launch of Unyvero BCU Blood Culture Application Cartridge

Jun 06 – Curetis and Axonlab sign multi-market European distribution agreement

May 20 – Curetis Publishes First Quarter 2016 Business and Financial Update

May 02 – Curetis shall hold its Annual General Shareholders’ Meeting on June 16, 2016

Apr 12 – Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance

Mar 24 – Curetis Announces Participation in Several Investor and Industry Conferences in Q2-2016

Mar 24 – Curetis to Publish its Annual Results 2015 on April 12, 2016

Mar 23 – Curetis to Launch CE-IVD Unyvero Blood Culture Application Cartridge at ECCMID 2016

Feb 23 – Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge

Feb 03 – Curetis Expands Commercial Team

Jan 11 – Curetis Establishes Medical Advisory Board with Internationally Renowned Experts

Jan 05 – Curetis Announces Participation in Several Investor and Industry Conferences

Dec 03 – Curetis Announces the Exercise of the Over-Allotment Option

Nov 10 – Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 million

Oct 29 – Curetis Announces New Supervisory Board of Curetis N.V.

Oct 28 – Curetis Announces its Initial Public Offering on Euronext in Amsterdam and Euronext in Brussels

Oct 14 – Curetis Announces Intention to Launch Its Initial Public Offering and Listing on Euronext Amsterdam and Euronext Brussels

Oct 05 – Curetis and Acumen to Collaborate on Unyvero Sepsis Test and ASEAN Distribution

Sep 25 – Curetis Enters into Distribution Agreement to Expand Commercial Activities into Greater China

Jul 08 – Curetis Initiates Next Phase of Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections

Jun 24 – Curetis’ Unyvero System Selected for Global Phase III Antibiotics Trial

May 11 – Curetis Strengthens Executive Team; Appoints Dr. Achim Plum as Chief Commercial Officer

Apr 20 – Curetis Expands Commercial Organization

Apr 16 – Curetis to Launch Next-Generation Pneumonia Application at ECCMID 2015

Mar 9 – Curetis Initiates Clinical CE Performance Evaluation of Unyvero P55 Pneumonia Application

Feb 17 – Curetis Presents Product Updates at Intensive Care Conference

Nov 24 – Curetis Closes EUR 14.5 Million Extension of Series B Financing

Oct 09 – Curetis Joins European Prosthetic Joint Infection Cohort Study (EPJIC)

Sep 30 – Curetis Presents New Unyvero Pneumonia Data at Major Clinical Microbiology Meetings

May 14 – Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero™ LRT Trial

May 07 – Curetis Launches Unyvero™ i60 Implant and Tissue Infection Cartridge in Europe

Apr 23 – New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application

Mar 27 – Curetis Obtains Key Patent for Unyvero™ Technology

Mar 04 – Curetis Prepares Launch of Second Unyvero™ Application

Jan 09 – Curetis and Laboratorios LETI Sign Exclusive Distribution Agreement for Unyvero™ in Spain and Portugal

Oct 30 – Curetis Receives Clearance for Unyvero™ System and Pneumonia Application in Russia and Serbia

Oct 22 – Curetis Presents First Data on Novel Unyvero™ i60 ITI Application for Implant and Tissue Infections

Oct 09 – Curetis Presents New Clinical Validation Data on its Unyvero™ P50 Pneumonia / LRT Application

Sep 18 – Curetis and Mediphos to Sponsor Expert Discussion on the Future of Infectious Diseases Testing

Sep 04 – Curetis to Present Clinical Unyvero™ Data at Major Scientific Conferences

Jun 09 – Curetis beginnt multizentrische Unyvero™ Studie in Europa

Apr 22 – Curetis raises EUR 12.5 million in Series B round led by new investor HBM Partners

Apr 17 – Curetis to Present Clinical Unyvero™ Data at ECCMID 2013 in Berlin

Mar 06 – Curetis AG Strengthens Commercial Team and Expands Distribution Network

Dec 06 – Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance

Dev 04 – Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of UnyveroTM Cartridge Plastics Parts

Oct 09 – Curetis Completes Enrollment for its EU Trial As Planned

Sep 27 – Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia

Sep 26 – Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherlands

Sep 20 – Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Diagnostic Cartridge

Sep 19 – Curetis AG to Present Its Unyvero™ Solution at DGHM Conference

trial of its antibiotic solithromycin (CEM-101)

Aug 09 – Cempra to use Curetis’ Unyvero™ solution in its Phase III

Jul 18 – Curetis AG Signs Distribution Deal in Middle East with ATC

May 14 – Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commercialization

Mar 20 – Curetis AG to Present Its Unyvero™ System for Pneumonia Diagnostics

Feb 16 – Curetis AG Initiates Prospective Clinical Trial for Rapid Pneumonia Diagnostics

Dec 13 – Curetis AG Appoints Dr. Klaus Brinkmann as Director of Sales

Oct 26 – Curetis AG attracts Forbion and Roche as new investors

Oct 18 – Curetis AG Opens Unyvero™ Cartridge Production Facility

May 17 – Curetis AG successfully increases Series A financing round to EUR 24.5 million

Apr 16 – Curetis AG and its Partners obtain Additional € 0.5 Million Funding under German Federal Innovation Grant Program

Dec 15 – Curetis appoints Oliver Schacht as CEO

Jul 12 – Curetis AG: Oliver Schacht elected as member of the Supervisory Board, Anne Burger appointed as CFO.

May 31 – Curetis AG increases Series A Financing to € 20 Million and receives ISO 13485 Certification

Dec 03 – € 18.5 million Series A Financing Round closed

Apr 14 – Joint R&D project of University Hospital Tübingen, NMI (Reutlingen) and Curetis AG (Holzgerlingen) has received public funding for the development of effective tools to diagnose infections